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Abstract 
Introduction: Cerebral small vessel disease (SVD) contributes to dementia and disability in the 
elderly, and may negatively affect stroke outcomes. We aimed to evaluate to what extent single 
features and global burden of SVD detected with magnetic resonance (MR) are associated with 
worse outcomes in patients with ischaemic stroke treated with intravenous thrombolysis.  
Methods: We accessed anonymised data and MR images from the Stroke Imaging Repository 
(STIR) and the Virtual International Stroke Trials Archive (VISTA) - Imaging. We described SVD 
features using validated scales and quantified the global burden of SVD with a combined score. Our 
main outcome was the modified Rankin Scale (mRS) at 90 days after stroke. We used logistic 
regression and ordinal regression models (adjusted for age, sex, stroke severity, onset to treatment 
time) to examine the associations between each SVD feature, SVD global burden and clinical 
outcomes. 
Results: A total of 259 patients had MR scans available at baseline (mean age±SD=68.7±15.5 
years; 131 [49%] males). After adjustment for confounders, severe white matter changes were 
associated with disability (OR=5.14;95%CI=2.30-11.48), functional dependency 
(OR=4.38;95%CI=2.10-9.13), and worse outcomes in ordinal analysis (OR=2.71;95%CI=1.25-
5.85). SVD score was associated with disability (OR=1.66;95%CI=1.03-2.66) and functional 
dependency (OR=1.47;95%CI=1.00-2.45). Lacunes, enlarged perivascular spaces and brain atrophy 
showed no association with clinical outcomes. 
Conclusion: our results suggest that SVD negatively affects stroke outcomes after intravenous 
thrombolysis. Although white matter changes seem to be the major driver in relation to worse 
outcomes, global estimation of SVD is feasible and may provide helpful information. 
 
 
Introduction 
Cerebral small vessel disease (SVD) refers to various pathological processes that affect 
microvasculature in the brain. The most common type of SVD is age/hypertension related SVD, 
widely recognized as a risk factor for stroke1 and as the cause of lacunar strokes, which account for 
around 25% of all ischaemic strokes2. Imaging hallmarks of SVD can be detected with both 
computer tomography (CT) and magnetic resonance (MR). Although useful information can be 
gathered from CT scan, routinely used in clinical practice for assessment of acute ischaemic stroke 
patients suitable for recombinant tissue-Plasminogen Activator (rt-PA) treatment, MR is the gold 
standard imaging for visualization in vivo of SVD. MR imaging phenotype of SVD ranges from 
white matter changes (WMCs) to enlarged perivascular spaces (EPVS)3, and MR is the first choice 
for imaging in non-acute stroke setting. 
A growing body of evidence, mostly from CT-based studies, focusses on the effect of a single 
feature of SVD (e.g. leukoaraiosis) on acute stroke treatment. Leukoaraiosis, the most extensively 
studied SVD feature in relation to acute ischaemic stroke and rt-PA treatment, and has been related 
to an increased risk of symptomatic intracerebral haemorrhagic transformation4,5,6 and worse 
clinical outcomes7,8,9. However, SVD is a heterogeneous process with a various imaging phenotype, 
and little is known about whether combinations of pre-existing imaging features can better convey 
predictive information on relevant outcomes. Staals et al. recently proposed a score8,9 to assess the 
global burden of SVD, introducing the concept that the whole spectrum of modifications rather than 
the single feature of SVD may provide valuable information for patients. Their score has been 
tested in a non-acute stroke scenario with MR assessment of SVD.  
The global assessment of SVD burden among acute stroke patients has been only partly tested in 
one study. In a cohort of patients treated with rt-PA, leukoaraiosis did not affect subsequent 
functional outcome, and only lacunes were associated with death4 . However, a re-analysis of the 
same dataset considering leukoaraiosis and lacunes as a combined score showed an independent 
association with both poor functional outcomes and symptomatic intracerebral hemorrhage after rt-
PA7.   
In the present study, we aimed to explore the relationship between single and combined imaging 
findings of SVD and clinical outcomes in a cohort of patients with ischaemic stroke and available 
MR imaging before rt-PA treatment.  
 
Methods 
We accessed patient level data from the STroke Image Repository (STIR)\Virtual International 
Stroke Trials Archive (VISTA) Imaging consortium (http://stir.tacc.utexas.edu) and conducted a 
retrospective analysis. STIR/VISTA-Imaging consortium has been established to promote 
excellence in stroke care and stroke trial design. The overall purpose is to create an international 
consortium of investigators and a repository of source MRI and CT images to promote 
standardization and validation of acquisition, analytic, and clinical research methods of image-
based stroke research.  
In the present study, we included patients with ischaemic stroke treated with intravenous (IV) rt-PA 
and accompanying MR based imaging before thrombolytic treatment. Additional ethical approval 
was not required since data were fully anonymous, from studies that had original ethical approval. 
Similarly, informed consent was not sought for the present study because data were anonymous. 
Clinical variables of interest included age, sex, baseline stroke severity assessed with National 
Institutes of Health Stroke Scale (NIHSS), onset to treatment time (OTT), baseline glucose, baseline 
blood pressure and cardiovascular risk factors. A stroke neurologist (FA), trained in MR assessment 
and blinded to clinical data, rated all the available scans (T1, T2, FLAIR sequences) for presence 
and severity of SVD features, according to STRIVE (STandards for ReportIng Vascular changes on 
nEuroimaging) recommendations2. We defined lacunes as round shaped cerebrospinal fluid 
isointense lesions measuring ≤20 mm in diameter on axial section in the white matter, basal ganglia 
or brainstem on T1, T2 or FLAIR sequences. We graded WMCs as 0-4 according to Van Swieten 
Scale (VSS) in anterior and posterior periventricular white matter13. Brain atrophy was defined as 
deep and cortical, and rated as none, mild-moderate and severe against a reference MR brain 
template14. EPVS were defined as ≤2mm round or linear cerebrospinal fluid isointense lesions (T2 
hyperintense and T1/FLAIR hypointense). We separately rated EPVS in basal ganglia and centrum 
semiovale using a 5-point ordinal scale15 as follows:  0=no EPVS, 1=1-10 EPVS, 2=11 to 20, 
EPVS, 3=21 to 40 EPVS, and 4= >40 EPVS.  
To generate a global estimate of SVD, we built up an aggregate SVD score. Although previous 
versions of the SVD score included also microbleeds and EPVS19, we only considered MR imaging 
features of SVD detectable with CT scan, to allow transferability of results on clinical practice. We 
therefore combined the scores of white matter changes, lacunes, and brain atrophy. We assigned 1 
point for each of the following: severe WMCs (VSS>=3), lacunes>=2 (multilacunar state) and 
severe brain atrophy, either central or cortical (>=2). The combined four-points ordinal score 
assessed the global burden of SVD from 0 (no imaging features of severe SVD) to 3 (imaging 
features of SVD scored as severe for each imaging variable). 
Our main outcome was the modified Rankin Scale (mRS) recorded 90 days after the index stroke. 
We considered mRS as ordinal scale (0-1=excellent outcome, 2-3=good outcome, 4-5=bad 
outcome, 6=death) and as dichotomous outcome (0-1 vs 2-6=disability/death; 0-2 vs 3-6=functional 
dependence/death; 6=death within three months). 
Statistical analysis: We described general characteristics of the study population using basic 
descriptive statistics as appropriate. Our explanatory variables were each imaging feature of SVD 
and the SVD score. We run univariate analysis and retain variables with p<0.1 in multivariate 
models. To assess independent associations, we adjusted univariate analysis for age, sex, NIHSS, 
OTT in both logistic and ordinal regression analysis. We considered p value<0.05 as statistically 
significant. Statistical analysis was carried out using SPSS for Windows (version 22.0; SPSS, 
Armonk NY, IBM Corp.). 
 
Results 
A total of 269 patients had available baseline MR scans. Ten scans were excluded for poor quality 
(movement artifacts and absence of relevant sequences), therefore 259 patients had scans available 
to assess white matter changes, brain atrophy and lacunes, whereas 164 patients had available T2 
axial-section to assess EPVS. Baseline characteristics of study population are showed in Table 1. 
Mean age was 68.7±15.5 years and 131 patients (49%) were male. Baseline median NIHSS was 10 
(IQR=6-17). Patients were treated with i.v. rt-PA with a mean of almost three hours after symptoms 
onset. Regarding SVD features, 92 (36%) of patients had severe WMCs, 49 (19%) had two or more 
lacunes, and 106 (41%) had severe brain atrophy. High number of EPVS (grade 2-4) were more 
common in the centrum semiovale (142 patients, 87%) than in the basal ganglia (92 patients, 56%). 
Figure 1 shows distributions of single SVD features according to their grade. A total of 117 (45%) 
patients had a SVD score of 0, showing no signs of either white matter changes, lacunes or brain 
atrophy. Around a half of the whole population had some grade of a SVD, namely a score of 1 or 2 
(n=118, 45%), and 23 patients (10%) had either severe white matter changes, two or more lacunes, 
and severe brain atrophy and scored SVD=3. Patients with increasing SVD score were older 
(p<0.001), were more likely prone to have hypertension and atrial fibrillation (Table 1).  
Outcome three months after the index stroke was available for 143 (55%) patients. Patients with 
available outcome had higher baseline NIHSS (11 vs 9; p=0.033) and higher OTT (187 vs 162 
minutes; p=0.002). There were no other differences with regard to relevant clinical variables 
(Supplemental Table 1). After three months from the index stroke, 90 (60%) patients had a mRS=2-
6 (disability/death); 77 (51%) patients had a mRS=3-6 (functional dependency/death); 41 patients 
(27%) died (mRS=6). Table 2 shows univariate and multivariate associations of SVD features and 
clinical outcomes. Multivariate logistic regression analysis confirmed the association between 
severe white matter changes and both disability/death (OR=4.74; 95% CI=1.69-13.29) and 
functional dependence/death (OR=3.62; 95% CI=1.38-9.50). Basal ganglia EPVS were associated 
with disability/death in univariate analysis (OR=2.47; 95% CI=1.13-5.43), however this association 
was confounded mainly by age in multivariate analysis (OR=1.84; 95% CI=0.66-5.12). Neither 
lacunes nor brain atrophy were associated with clinical outcomes. SVD score was independently 
associated with both disability/death (OR=1.66 per SVD score point increase; 95% CI=1.03-2.66) 
and functional dependence/death (OR=1.47 per SVD score point increase; 95% CI=1.00-2.45; 
p=0.050). None of the SVD radiological features showed association with death. After adjustment 
for age, sex, NIHSS and OTT, ordinal analysis showed that presence of severe white matter changes 
was independently associated with a shift towards worse outcomes (OR=2.71; 95% CI=1.25-5.85). 
Although not statistically significant, we found the same direction of association in patients with 
moderate-severe (grade 2 and 3) SVD score (OR=1.94; 95% CI=0.92-4.09; p=0.087) (Figure 2). 
 
Discussion 
We found that in a small cohort of ischaemic stroke patients treated with IV rt-PA, severe pre-
existing WMCs were associated with increased odds of poor clinical outcome. Global burden of 
SVD quantified with a combined score was also associated with disability and functional 
dependency. Lacunes, brain atrophy and EPVS showed no association with relevant clinical 
outcomes. 
Our findings regarding WMCs are in keeping with previous larger studies that showed a negative 
association between WMCs grade and clinical outcomes8,9. We built on these studies by applying 
the gold standard tool for detection of SVD features3 (i.e. MR) and confirmed the effect of WMCs 
on outcome on a smaller dataset. As a common imaging marker of SVD, WMCs could affect stroke 
outcomes through various mechanisms. In the hyperacute phase of ischaemic stroke, WMCs may 
influence the infarct volume and are associated with a larger growth of the infarct size16, 17,18. 
WMCs are also associated with larger cortical infarcts after distal arterial occlusion19, suggesting 
that microcirculation could be affected also in the grey matter and therefore lead to greater cerebral 
damage. Patients with WMCs display reduced vascular density20, impaired cerebral perfusion21 and 
SVD is related to both endothelial dysfunction and blood brain barrier leakage, which are thought to 
be key drivers of its pathophysiology22,23,24. Furthermore, rheological modifications such as 
increased platelet activation25 and a pro-coagulative status may occur together with SVD26. Each of 
the aforementioned physiopathological processes related to SVD may eventually result in a larger 
infarct size, impaired reperfusion after recanalization therapy and, from a clinical point of view, in 
worse outcomes after stroke.  
Although our study sample was smaller than previous studies8,9, we found statistically significant 
associations. Compared to plain CT scan, MR is more sensitive in detection of WMCs13,27, hence it 
is reasonable that larger sample sizes are required to reach significant results when using CT, 
particularly regarding the evaluation of WMCs. On the other hand, agreement of visual rating scales 
for WMCs between MR and CT is fairly good28, and both WMCs and brain atrophy scales have 
been validated for MR and CT8,13. Conversely to a previous larger study4, we did not found any 
independent association between lacunes and clinical outcomes. The sample size and the 
consequent lack of adequate statistical power may be the reason for this discrepancy.   
We also investigated EPVS in relation to acute stroke outcomes. EPVS are an imaging hallmark of 
SVD and have been associated with cognitive decline after stroke29,30. We found EPVS common in 
patients with stroke, and their relation with clinical outcomes may be of clinical interest. We found 
a significant association with poor outcomes in the univariate analysis; however our study was 
likely underpowered to demonstrate an independent association after multivariable adjustment. 
Future studies may specifically address whether EPVS have a predictive role in stroke outcome and 
in patients treated with rt-PA or mechanical thrombectomy. 
SVD features frequently occur together, and we tried to quantify the cumulative effect of combined 
signs. Considerably, we found signs of two or more severe SVD features in around one third of our 
patients, and this negatively affected clinical outcomes. Therefore, we showed that quantification of 
global burden of SVD is feasible and has clinical relevance, as previously suggested by other 
groups10,11. We did not assess the entire imaging phenotype of SVD detectable with MR, rather we 
chose features visible with both MR and plain CT scan to enhance the feasibility of use in clinical 
practice. We observed a meaningful association between the SVD score and clinical outcomes, with 
WMCs acting as the driving feature for poor outcome. We acknowledge that the SVD score 
requires further validation with larger sample size in acute stroke setting and with CT scan 
evaluation of SVD features. However, if validated, the score might be applied in both clinical 
practice and clinical trials and increase the power to predict outcomes. Moreover, in an acute stroke 
scenario, the use of the SVD score may redress CT limitations in the detection of single SVD 
features and provide more accurate estimates about stroke prognosis. 
The strengths of our study include the blinded rating of SVD features, the use of the gold standard 
for SVD assessment in vivo (i.e. MR imaging), and the qualitative rating of SVD features with 
extensively validated scales, easily transferrable to clinical practice. The small sample size is the 
main limitation of our study, and we recognize that our results related to the SVD score need 
external validation in larger cohorts. Another limit is the number (almost a half) of patients with 
missed outcomes at follow-up. Assuming that missed patients generally face worse outcomes 
compared to non-missed patients, one could argue that our patients with available outcomes had a 
milder stroke profile. However, the comparison of baseline characteristics of included and excluded 
patients does not seem to support this attrition bias. In fact, stroke severity and OTT, two of the 
most important predictors of unfavourable outcomes, were higher (i.e. increased odds of poor 
outcome) in the population with available outcomes at follow-up.  
In conclusion, we showed that in a cohort of MR-based imaging patients with acute ischaemic 
stroke treated with IV rt-PA, WMCs are frequent and associated with disability, functional 
dependency and a shift towards worse outcomes in ordinal analysis. We also utilized a combined 
score that takes into account pre-existing global burden of SVD radiological features and found the 
score associated with disability and functional dependency. The SVD score is potentially feasible 
for application in an acute stroke setting, and after validation for CT scan could inform the risk of 
attaining a poorer outcome after rt-PA treatment, particularly in patients with two or more signs of 
severe SVD; this may also inform the design of future clinical trials. Our results lend support to the 
theory that SVD may act as a marker of brain frailty; the presence of SVD, and particularly WMCs, 
have negative effects on clinical outcomes. 
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Table 1. Demographic and clinical characteristics of study population according to SVD score. 
SD=Standard deviation; NIHSS=National Institutes of Health Stroke Scale; IQR=Interquartile 
Range; OTT=Onset To Treatment time; BP=Blood Pressure; TIA=Transient Ischaemic Attack. 
Data are numbers (%) unless otherwise stated.  
 
 
 
 
 
 
 
 
  SVD score  
Variables Total 
population 
N=259 
0 
(n=117) 
1 
(n=59) 
2 
(n=59) 
3 
(n=23) 
p 
Age, mean (±SD) 69.7±15.5 60.9±15.5 72.4±13.2 80.2±7.8 80.5±7.6 <0.001 
Sex, male 131 (49) 61 (52) 27 (46) 28 (48) 10 (48) 0.791 
Baseline NIHSS, median (IQR) 10 (6-17) 9 (5-15) 10 (6-19) 13 (8-19) 11 (7-15) 0.047 
OTTT, mean (±SD) 176.32±62.4 171.4±60.8 181.5±65.5 175.6±63.8 200.7±65.0 0.245 
Glucose, mean (±SD) 133.1±51.6 132.5±52.9 128.5±40.7 130.7±38.3 153.8±85.4 0.226 
Systolic BP,  mean (±SD) 152.2±26.2 148.4±24.0 154.2±29.6 159.1±28.1 152.0±23.5 0.255 
Diastolic BP,  mean (±SD) 81.9±15.2 79.3±13.2 85.5±17.4 84.3±16.1 81.0±14.2 0.130 
Diabetes 57 (21) 23 (20) 14 (23) 11 (19) 8 (35) 0.381 
Hypertension 185 (69) 68 (58) 50 (85) 45 (76) 19 (83) 0.001 
Atrial fibrillation 79 (29) 22 (19) 20 (34) 26 (44) 10 (44) 0.002 
Hyperlipidemia 123 (46) 54 (46) 34 (58) 23 (39) 9 (39) 0.188 
Smoke 73 (27) 32 (27) 13 (22) 17 (29) 7 (30) 0.806 
Table 2. Unadjusted and adjusted associations between radiological features of small vessel disease 
and clinical outcomes. 
 Unadjusted OR (95% CI) Adjusted OR (95% CI) 
 Variables mRS=2-6  mRS=3-6 mRS=6 mRS=2-6 mRS=3-6 mRS=6 
Severe WMCs 5.14 (2.30-11.48) 4.38 (2.10-9.13) 2.60 (1.21-5.59) 4.74 (1.69-13.29) 3.62 (1.38-9.50) 1.72 (0.65-4.60) 
Two or more lacunes 1.77 (0.71-4.39) 1.84 (0.77-4.39) 0.65 (0.23-1.88) - - - 
Basal ganglia EPVS 2.47 (1.13-5.43) 1.72 (0.80-3.68) 2.38 (0.95-5.95) 1.84 (0.66-5.12) - - 
Centrum semiovale EPVS 1.36 (0.46-3.96) 1.18 (0.41-3.41) 1.11 (0.33-3.77) - - - 
Central brain atrophy 1.65 (1.06-2.57) 1.52 (0.98-2.36) 1.17 (0.71-1.93) 0.94 (0.48-1.83) - - 
Cortical brain atrophy 1.49 (0.87-2.57) 1.54 (0.90-2.62) 1.11 (0.61-2.02) - - - 
SVD score 1.93 (1.32-2.81) 1.88 (1.31-2.69) 1.25 (0.87-1.81) 1.66 (1.03-2.66) 1.47 (1.00-2.45) - 
WMCs=White Matter Changes; EPVS=Enlarged Perivascular Spaces; SVD=Small Vessel Disease; 
OR=Odds Ratio; CI=Confidence Interval; mRS=modified Rankin Scale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Distribution of SVD features according to their severity. 
 
 
 
  
 
 
 
  
 
 
 
SVD=Small Vessel Disease; WMCs=White Matter Changes; EPVS=Enlarged Perivascular Spaces. N for WMCs and brain atrophy=259; N for lacunes=258; N for EPVS=164. 
Figure 2. Crude rates of effect of severe white matter changes (WMCs) and SVD score on 
cathegorized mRS. Odds ratios are from ordinal regression analysis adjusted for age, sex, baseline 
NIHSS, onset to treatment time. 
 
